PDS Biotechnology (NASDAQ:PDSB) Upgraded by StockNews.com to “Sell”

StockNews.com upgraded shares of PDS Biotechnology (NASDAQ:PDSB) to a sell rating in a research report sent to investors on Monday.

Separately, HC Wainwright reaffirmed a buy rating and issued a $21.00 target price on shares of PDS Biotechnology in a research report on Monday, August 14th.

PDS Biotechnology Stock Performance

Shares of PDSB opened at $5.89 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.02 and a quick ratio of 8.02. PDS Biotechnology has a one year low of $2.89 and a one year high of $13.65. The company has a 50-day simple moving average of $5.54 and a two-hundred day simple moving average of $6.20. The firm has a market capitalization of $181.81 million, a PE ratio of -3.64 and a beta of 1.93.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Monday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). On average, analysts anticipate that PDS Biotechnology will post -1.54 EPS for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new stake in PDS Biotechnology in the second quarter valued at approximately $47,000. Nuveen Asset Management LLC acquired a new stake in shares of PDS Biotechnology during the second quarter worth $529,000. Alliancebernstein L.P. acquired a new stake in shares of PDS Biotechnology during the second quarter worth $190,000. Wells Fargo & Company MN lifted its stake in shares of PDS Biotechnology by 219.3% during the second quarter. Wells Fargo & Company MN now owns 17,241 shares of the company’s stock worth $87,000 after buying an additional 11,841 shares during the period. Finally, Kennedy Capital Management LLC acquired a new stake in shares of PDS Biotechnology during the second quarter worth $51,000. 25.78% of the stock is owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.